î
îŒ
î
Kamada Ltd
KMDAî¹
詳现ãã£ãŒãã衚瀺
7.070USD
-0.020-0.28%
çµå€Â 12/26, 16:00ïŒETïŒ15åé
ãã®æ ªäŸ¡
407.81Mæ䟡ç·é¡
20.11çŽè¿12ã¶æPER
î
Intraday
1m
30m
1h
D
W
M
D
æ¬æ¥
-0.28%
5æ¥é
-2.88%
1ã¶æ
+3.97%
6ã¶æ
-8.30%
幎åæ¥
+16.09%
1幎é
+19.53%
詳现ãã£ãŒãã衚瀺
TradingKeyã®Kamada Ltdã®æ ªåŒã¹ã³ã¢î
é貚: USD æŽæ°æå»: 2025-12-26äž»èŠã€ã³ãµã€ã
Kamada Ltdã®ãã¡ã³ãã¡ã³ã¿ã«ãºã¯æ¯èŒçéåžžã«å¥å šã§ããæé·ã®å¯èœæ§ã¯é«ãã§ããããªã¥ãšãŒã·ã§ã³ã¯é©æ£äŸ¡æ Œãšè©äŸ¡ãããŠããŸãã å»è¬åæ¥çã®ã©ã³ãã³ã°ã¯55/158äœã§ããæ©é¢æè³å®¶ä¿æçã¯éåžžã«é«ãã§ããéå»1ãæéã«è€æ°ã®ã¢ããªã¹ããè²·ããšè©äŸ¡ããæé«ç®æšæ ªäŸ¡ã¯13.00ãšãããŠããŸããäžæçã«ã¯ãæ ªäŸ¡ã¯å®å®æšç§»ãšäºæ³ãããŸããå瀟ã¯éå»1ãæéãæ ªåŒåžå Žã§å¥œèª¿ãªããã©ãŒãã³ã¹ã瀺ããŠãããããã¯å匷ããã¡ã³ãã¡ã³ã¿ã«ãºãšãã¯ãã«ã«ã«è£ä»ããããŠããŸããæ ªäŸ¡ã¯æ¯æç·ãšæµæç·ã®éã§æšªã°ãæšç§»ããŠãããã¬ã³ãžçžå Žã§ã®ã¹ã€ã³ã°ãã¬ãŒãã«é©ããŠããŸãã
Kamada Ltdã®ã¹ã³ã¢î°î°
æ¯æç·ãšæµæç·
äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
ã¬ãŒããŒãã£ãŒã
çŸåš
ååå€
ã¢ããªã¹ãç®æšæ ªäŸ¡
3
人ã®ã¢ããªã¹ãäºæ³ã«åºã¥ã
è²·ã
çŸåšã®è©äŸ¡
13.000
ç®æšæ ªäŸ¡
+93.16%
äžæäœå°
å
責äºé
ïŒã¢ããªã¹ãã®ã¬ãŒãã£ã³ã°ããã³ç®æšæ ªäŸ¡ã¯ãæ
å ±æäŸã®ã¿ãç®çãšããŠLSEG Data & AnalyticsãæäŸãããã®ã§ãããæè³å©èšãæ§æãããã®ã§ã¯ãããŸããã
Kamada Ltdã®æ³šç®ãã€ã³ã
匷ã¿ãªã¹ã¯
Kamada Ltd is Israel based company, focused on plasma-derived protein therapeutics with a commercial product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.
é«æé·
å瀟ã®åçã¯éå»3幎éã«ãããçå®ã«å¢å ããŠããã幎平åã§24.44%ã®æé·çã瀺ããŠããŸãã
é©æ£æ°Žæº
å瀟ã®ææ°ã®PEã¯20.11ã§ãéå»3幎éã®æ°Žæºãšæ¯èŒããŠé©æ£åã«ãããŸãã
æ©é¢æè³å®¶ã®å£²ãè¶ã
ææ°ã®æ©é¢æè³å®¶ã®ä¿ææ ªæ°ã¯26.81Mæ ªã§ãåååææ¯ã§10.38%æžå°ããŠããŸãã
ãã£ãµãªã³ã»ãŠãããä¿æ
ã¹ã¿ãŒæè³å®¶ãã£ãµãªã³ã»ãŠããã¯æ¬éæã256.22Kæ ªä¿æããŠããŸãã
Kamada Ltd ãã¥ãŒã¹
ææ°æ
å ±ããåŸ
ã¡ãã ãã...
財åææšî
EPS
äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
ç·å£²äžé«
äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
Kamada Ltdã®äŒæ¥æ å ±î
Kamada Ltd is Israel based company, focused on plasma-derived protein therapeutics with a commercial product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.
äŒæ¥ã³ãŒãKMDA
äŒæ¥åKamada Ltd
æé«çµå¶è²¬ä»»è
ãCEOãLondon (Amir)
ãŠã§ããµã€ãhttps://www.kamada.com/
ãããã質å
Kamada LtdïŒKMDAïŒã®çŸåšã®æ ªäŸ¡ã¯ãããã§ããïŒ
îKamada LtdïŒKMDAïŒã®çŸåšã®æ ªäŸ¡ã¯7.070ã§ãã
Kamada Ltdã®ãã£ãã«ãŒã·ã³ãã«ã¯äœã§ããïŒ
îKamada Ltdã®ãã£ãã«ãŒã·ã³ãã«ã¯KMDAã§ãã
Kamada Ltdã®52é±é«å€ã¯ãããã§ããïŒ
îKamada Ltdã®52é±é«å€ã¯9.155ã§ãã
Kamada Ltdã®52é±å®å€ã¯ãããã§ããïŒ
îKamada Ltdã®52é±å®å€ã¯5.540ã§ãã
Kamada Ltdã®æ䟡ç·é¡ã¯ãããã§ããïŒ
îKamada Ltdã®æ䟡ç·é¡ã¯407.81Mã§ãã
Kamada Ltdã®çŽå©çã¯ãããã§ããïŒ
îKamada Ltdã®çŽå©çã¯14.46Mã§ãã
Kamada Ltd (KMDA) ã®çŸåšã®è©äŸ¡ã¯ãè²·ããããããŒã«ãããã売ããã®ã©ãã§ããïŒ
îã¢ããªã¹ãã«ãããšãKamada LtdïŒKMDAïŒã®ç·åè©äŸ¡ã¯è²·ãã§ãç®æšæ ªäŸ¡ã¯13.000ã§ãã
Kamada Ltd (KMDA) ã®1æ ªåœããå©çïŒEPS TTMïŒã¯ãããã§ããïŒ
îKamada LtdïŒKMDAïŒã®1æ ªåœããå©çïŒEPS TTMïŒã¯0.352ã§ãã
é¢é£éèåå
+0.05%
-0.07%
+0.08%
+0.49%
+0.23%
+0.38%
-0.31%
-0.30%
-0.77%
+0.30%
+0.23%
-0.02%
-0.07%
+0.24%
+0.26%
+0.30%
+0.16%
0.00%
+0.58%
-0.02%人æ°éæ
